CUT MIX 225

PRODUCT OVERVIEW

Specification	Details
Generic Name	**Cut Mix 225**
Drug Class	**Multi-Compound Anabolic-Androgenic Steroid Blend**
Active Ingredient	Trenbolone Acetate / Drostanolone Propionate / Testosterone Propionate
Administration Route	**Intramuscular Injection**
Dosage Form	**Injectable Oil-Based Solution**
Total Concentration	**225 mg/mL**
Primary Target	**Androgen Receptor (AR)**
Clinical Status	**Non-approved multi-compound anabolic steroid formulation**

INTRODUCTION

Cut Mix 225 is a multi-compound injectable anabolic-androgenic steroid formulation containing Trenbolone Acetate 75 mg/mL, Drostanolone Propionate 75 mg/mL, and Testosterone Propionate 75 mg/mL, providing a combined steroid concentration of 225 mg/mL.

The formulation combines three short-acting esterified androgens with distinct parent hormones. Testosterone provides testosterone-mediated androgenic activity, drostanolone is a DHT-derived androgenic steroid, and trenbolone is a potent 19-nortestosterone-derived androgen. All three compounds exert substantial activity through androgen-receptor signaling, while their propionate and acetate esters produce comparatively rapid release following intramuscular administration.

HISTORY

The three components of Cut Mix 225 originate from different areas of androgen pharmacology. Testosterone propionate was among the earliest esterified testosterone preparations developed for therapeutic use, providing a shorter-duration alternative to later long-acting testosterone esters. Drostanolone propionate was subsequently developed as a synthetic DHT-derived anabolic-androgenic steroid and historically had limited medical use, including treatment of certain forms of breast cancer in women. Trenbolone acetate was developed later as a potent 19-nortestosterone derivative and has become associated with veterinary applications and illicit performance formulations combining these three components as a single "Cut Mix" are not recognized as approved therapeutic medicines and should be regarded as non-approved multi-androgen formulations.

CHEMICAL STRUCTURE

Cut Mix 225 combines three esterified anabolic-androgenic compounds with distinct steroid structures. Trenbolone Acetate is a 19-nortestosterone derivative containing an acetate ester, while Drostanolone Propionate is a DHT-derived androgen 2α-methyl DHT-esterified with propionic acid.

Testosterone Propionate is the propionate ester of testosterone, with esterification at the 17β-hydroxyl group. After enzymatic hydrolysis, the three esters release their respective active hormones: trenbolone, drostanolone, and testosterone.

CHEMICAL PROFILE

Parameter	Information
Primary Components	**Multiple Trenbolone Esters**
Hormone Classification	**Anabolic-Androgenic Steroid**
Administration	**Intraocular Injection**
Dosage Form	**Oil-Based Injectable Solution**
Parent Hormone	**Trenbolone**
Structural Family	**19-Nortestosterone Derivative**

PHARMACOLOGY

Cut Mix 225 combines three esterified anabolic-androgenic compounds whose primary biological activity converges on the androgen receptor.

Trenbolone Acetate is a potent 19-nortestosterone-derived androgen with strong androgen-receptor affinity. Drostanolone Propionate releases drostanolone, a DHT-derived androgen that does not undergo aromatization to estrogen. Testosterone Propionate releases testosterone, which exerts androgenic effects and undergoes conversion to estradiol through aromatase and to dihydrotestosterone through 5α-reductase.

The combination therefore produces overlapping androgen-receptor activity while retaining the distinct metabolic characteristics of each active hormone.

MECHANISM OF ACTION

Following intramuscular administration, the esterified compounds are gradually released from the oil depot.

The mechanism involves:

- Release of the three esterified compounds from the intramuscular depot
- Enzymatic hydrolysis of the acetate and propionate ester groups
- Systemic distribution of trenbolone, drostanolone, and testosterone
- Binding of the active hormones to intracellular androgen receptors
- Activation and nuclear translocation of androgen-receptor complexes
- Regulation of androgen-responsive gene transcription
- Modification of protein metabolism and androgen-sensitive cellular activity

PHARMACODYNAMICS

Cut Mix 225 affects multiple physiological systems through combined androgen-receptor signaling.

SKELETAL MUSCLE SYSTEM

Anabolic-androgenic steroids interact with androgen receptors in skeletal muscle and may influence:

- Protein metabolism
- Muscle tissue maintenance
- Nitrogen retention
- Myogenic differentiation

Androgen-receptor signaling contributes to the regulation of normal skeletal muscle structure and function.

SKELETAL SYSTEM

Androgen-receptor signaling contributes to skeletal physiology and may influence:

- Bone metabolism
- Bone mineral maintenance
- Bone remodeling
- Structural integrity

CONNECTIVE TISSUE

Androgen-receptor signaling may influence connective tissue physiology through:

- Structural protein metabolism
- Tissue maintenance
- Tissue remodeling
- Collagen metabolism

REPRODUCTIVE SYSTEM

Androgenic compounds interact with androgen-sensitive tissues and may influence:

- Hormonal regulation
- Endocrine signaling
- Reproductive physiology
- Androgen-responsive tissues

PHARMACOKINETICS

Following intramuscular administration, Cut Mix 225 forms an oil-based depot within muscle tissue. Trenbolone Acetate contains a short acetate ester, while Drostanolone Propionate and Testosterone Propionate contain short propionate esters.

Enzymatic hydrolysis gradually releases active trenbolone, drostanolone, and testosterone into systemic circulation. Because the formulation contains three separate active compounds, it does not have one universal pharmacokinetic half-life. Each component follows its own absorption, hydrolysis, distribution, metabolism, and elimination profile.

PHYSIOLOGICAL EFFECTS

Cut Mix 225 produces combined androgenic activity through trenbolone, drostanolone, and testosterone. Activation of androgen receptors in skeletal muscle and other androgen-responsive tissues can influence protein synthesis, nitrogen balance, muscle protein turnover, erythropoiesis, skeletal physiology, connective-tissue metabolism, and general androgen-dependent physiology.

The three active hormones differ in their secondary metabolism. Testosterone can undergo aromatization to estradiol and conversion to DHT, whereas drostanolone is already a DHT-derived compound and does not aromatize. Trenbolone is a 19-nortestosterone derivative with potent androgen-receptor activity and does not undergo meaningful aromatization. Despite the commercial designation "Cut Mix," the formulation itself does not have an established medical indication for fat loss or weight reduction.

CLINICAL APPLICATIONS

The individual components have different historical pharmacological applications. Testosterone Propionate has been used medically as an androgen replacement therapeutic. Drostanolone Propionate historically had limited therapeutic applications, and Trenbolone Acetate has primarily been associated with veterinary medicine.

The specific combination of Trenbolone Acetate 75 mg/mL, Drostanolone Propionate 75 mg/mL, and Testosterone Propionate 75 mg/mL does not have an established approved human therapeutic indication. Clinical evaluation of exposure to such compounds would require consideration of cardiovascular, endocrine, hematological, hepatic, renal, and reproductive parameters.

SAFETY CONSIDERATIONS

The use of anabolic-androgenic steroids may require consideration of cardiovascular, hematological, hepatic, endocrine, metabolic, and reproductive health.

Important safety considerations include:

- Cardiovascular health
- Blood pressure
- Hematological parameters
- Lipid profiles
- Liver function
- Kidney function
- Reproductive function
- Prostate health

The overall safety profile depends on the specific compound, formulation, concentration, duration of exposure, individual response, and clinical characteristics. Appropriate medical evaluation and regular monitoring should be considered when clinically indicated.

POTENTIAL ADVERSE EFFECTS

Potential adverse effects associated with anabolic-androgenic steroid exposure may involve endocrine, cardiovascular, hematological, hepatic, dermatological, reproductive, and metabolic systems.

Endocrine Effects
- Suppression of endogenous hormone production
- Alterations in hormonal balance
- Changes in reproductive hormone signaling
- Potential suppression of spermatogenesis

Cardiovascular Effects
- Changes in lipid profile
- Possible increases in blood pressure
- Potential cardiovascular risk

Hematological Effects
- Changes in hematocrit
- Changes in hemoglobin
- Possible increase in erythropoietic activity

Dermatological Effects
- Acne
- Increased sebaceous activity
- Androgen-related hair loss in genetically predisposed individuals

Reproductive Effects
- Changes in reproductive function
- Potential reduction in fertility
- Alterations in reproductive hormone regulation

Hepatic & Metabolic Effects
- Changes in liver function parameters
- Alterations in cholesterol levels
- Changes in glucose and lipid metabolism

The occurrence and severity of adverse effects vary according to the specific compound, formulation, exposure, duration of use, individual response, and patient characteristics.

CONTRAINDICATIONS

Condition	Reason
Prostate Cancer	**Potential androgen sensitivity**
Male Breast Cancer	**Risk of fetal virilization**
Pregnancy	**Potential worsening of cardiovascular risk**
Severe Cardiovascular Disease	**Requires specialist evaluation**
Severe Hepatic or Renal Disease	**Potential further increase in hematocrit**

DRUG INTERACTIONS

A comprehensive interaction profile may not be established for every anabolic-androgenic steroid or formulation.

Potential interactions or clinical considerations may exist with:

- Anticoagulants
- Hepatotoxic medications
- Hepatotoxic medications
- Other anabolic-androgenic steroids
- Other hormonal therapies
- Drugs affecting lipid metabolism

The clinical significance of potential interactions depends on the specific compound, formulation, dosage, duration of exposure, concomitant medications, and individual patient characteristics. Appropriate medical evaluation should be considered when multiple medications or hormonal therapies are used concurrently.

LABORATORY MONITORING

Laboratory Test	Purpose
CBC	**Monitor hematological parameters**
ALT / AST	**Liver function**
Bilirubin	**Hepatic assessment**
Lipid Profile	**Cardiovascular risk assessment**
Blood Pressure	**Cardiovascular monitoring**
Total Testosterone	**Assess androgen status**
LH / FSH	**Assess endocrine suppression**

STORAGE & STABILITY

- Store according to official product labeling.
- Protect from excessive heat and direct sunlight.
- Do not freeze.
- Maintain original packaging integrity.
- Keep away from children.
- Inspect packaging before use.

PRODUCT AUTHENTICITY

Every genuine NEXON product should include appropriate quality verification features.

Authentication may include:

- Batch number tracking
- Manufacturing information
- Expiration date verification
- QR authentication system
- Authorized distribution verification

NEXON emphasizes transparency, traceability, and product quality control.

FREQUENTLY ASKED QUESTIONS

What is Cut Mix 225?
Cut Mix 225 is a multi-compound injectable formulation containing Trenbolone Acetate 75 mg/mL, Drostanolone Propionate 75 mg/mL, and Testosterone Propionate 75 mg/mL.

What is the total concentration?
The total active concentration is 225 mg/mL.

Are all three components short-acting?
Yes. Trenbolone uses an acetate ester, while Drostanolone and Testosterone use propionate esters. These are relatively short ester structures compared with longer esters such as enanthate.

Do all three components release the same hormone?
No. They release three different active hormones: trenbolone, drostanolone, and testosterone.

Does Cut Mix 225 convert to estrogen?
The Testosterone Propionate component can undergo aromatization to estradiol. Trenbolone and Drostanolone do not undergo conventional aromatization.

Is Drostanolone a DHT derivative?
Yes. Drostanolone is structurally derived from dihydrotestosterone (DHT).

NEXON QUALITY COMMITMENT

NEXON is committed to maintaining high standards of manufacturing quality, product consistency, traceability, and scientific transparency.

Through quality control systems, authentication procedures, and responsible information sharing, NEXON aims to provide reliable pharmaceutical products and educational resources for healthcare professionals and informed users.

SCIENTIFIC REFERENCES

1. Yesalis CE, Bahrke MS. Anabolic-Androgenic Steroids.

2. Bidlack WR. Androgen Abuse in Athletes: Detection and Consequences.

3. Handelsman DJ. Androgen Physiology and Pharmacology.

4. Shahidi NT. Chemistry, Biological Action and Clinical Applications of Anabolic-Androgenic Steroids.

5. Llewellyn W. Anabolics.

6. Evans NA. Current Concepts in Anabolic-Androgenic Steroids.

7. Kochakian CD. Anabolic-Androgenic Steroids.

8. Nieschlag E, Behre HM. Andrology: Male Reproductive Health and Dysfunction.

9. Kicman AT, Gower DB. Anabolic Steroids in Sport and Exercise.

10. Wilson JD. Androgen Physiology and Pharmacology.